We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

25 hedge funds and large institutions have $312K invested in Biolase, Inc. in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

14% more funds holding

Funds holding: 22 → 25 (+3)

79% less capital invested

Capital invested by funds: $1.49M → $312K (-$1.17M)

Holders
25
Holders Change
+3
Holders Change %
+13.64%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$238K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$161K
3
APP
Avantax Planning Partners
Iowa
+$91.1K
4
Millennium Management
Millennium Management
New York
+$68.1K
5
TSS
Two Sigma Securities
New York
+$26.9K

Top Sellers

Rank Fund Capital Flow
1
AIC
AWM Investment Company
New York
-$545K
2
PCM
Perkins Capital Management
Minnesota
-$430K
3
Renaissance Technologies
Renaissance Technologies
New York
-$39K
4
Prudential Financial
Prudential Financial
New Jersey
-$16.5K
5
VF
Virtu Financial
New York
-$2.11K
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
1
Walleye Capital
New York
$100K +$238K +14,205 New
Acadian Asset Management
2
Acadian Asset Management
Massachusetts
$67K +$161K +9,617 New
APP
3
Avantax Planning Partners
Iowa
$38.5K +$91.1K +5,441 New
Millennium Management
4
Millennium Management
New York
$28.8K +$68.1K +4,068 New
ZF
5
Zhang Financial
Michigan
$11.7K +$24.1K +1,440 +689%
TSS
6
Two Sigma Securities
New York
$11.4K +$26.9K +1,609 New
PCM
7
Perkins Capital Management
Minnesota
$11K -$430K -25,663 -94%
BlackRock
8
BlackRock
New York
$8.37K – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$6.67K – – –
Commonwealth Equity Services
10
Commonwealth Equity Services
Massachusetts
$5K +$8.37K +500 +195%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$3.88K – – –
VF
12
Virtu Financial
New York
$3K -$2.11K -126 -21%
HF
13
HRT Financial
New York
$3K +$8.67K +518 New
UBS Group
14
UBS Group
Switzerland
$2.89K +$6.21K +371 +1,031%
Bank of Montreal
15
Bank of Montreal
Ontario, Canada
$2.85K +$5.69K +340 New
CSS
16
Cubist Systematic Strategies
Connecticut
$2.53K +$5.99K +358 New
Northern Trust
17
Northern Trust
Illinois
$2.12K – – –
State Street
18
State Street
Massachusetts
$1.23K – – –
BBA
19
Baader Bank Aktiengesellschaft
Germany
$599 +$117 +7 +7%
TRCT
20
Tower Research Capital (TRC)
New York
$516 – – –
Osaic Holdings
21
Osaic Holdings
Arizona
$375 +$820 +49 +1,633%
Morgan Stanley
22
Morgan Stanley
New York
$73 -$50 -3 -23%
Wells Fargo
23
Wells Fargo
California
$14 – – –
IA
24
IFP Advisors
Florida
$6 – – –
Fidelity Investments
25
Fidelity Investments
Massachusetts
$2 – – –
1
2

BIOL Hedge Fund Activity: Q2 2023 in Review

25 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q2 2023, worth a combined $312K — down 79% from $1.49M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BIOL positions and 5 closed out — a net gain of 3 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Walleye Capital, opening a new position worth an estimated $238K. The largest seller was AWM Investment Company, exiting entirely with an estimated $545K sold.

  • 25 institutional investors held Biolase, Inc. (BIOL) as of Q2 2023, up from 22 in Q1 2023.
  • Funds reported $312K of Biolase, Inc. stock for Q2 2023, down 79% quarter-over-quarter.
  • 8 funds opened new Biolase, Inc. positions in Q2 2023 and 5 closed out, a net change of +3 holders.
  • The largest Biolase, Inc. buyer in Q2 2023 was Walleye Capital, an estimated $238K added.
  • The largest Biolase, Inc. seller in Q2 2023 was AWM Investment Company, an estimated $545K sold.

Based on aggregated 13F filings for Q2 2023.